drugset / Trial / NCT02845908
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.
Timeline
- Start
- 2015-11
- Primary completion
- 2018-05
- Completion
- 2020-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Other |
| Background | Leucovorin | Small molecule | 200 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |